• The Cooper Companies raised fiscal 2026 guidance, updated Sept. 9, projecting total revenue of $4.23-$4.25 billion.
• Organic revenue growth outlook set at 2%-3%, led by CooperSurgical at 4%-5% versus CooperVision at 1%-2%.
• Non-GAAP EPS forecast at $4.51-$4.55, implying Q4 non-GAAP EPS of $1.05-$1.09.
• Q4 revenue expected at $1.06-$1.08 billion, including CooperVision $692-$706 million, CooperSurgical $364-$374 million.
• Free cash flow objective set above $2.2 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Cooper Companies Inc. published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.